José Luis Buleje

Dr. José Luis Buleje

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CVCarlos Alberto Vaccaro
Carlos Alberto Vaccaro
FLFrancisco López‐Kostner
Francisco López‐Kostner
DADella Valle Adriana
Della Valle Adriana
EPEdenir Palmero
Edenir Palmero
BRBenedito Mauro Rossi
Benedito Mauro Rossi
IGin collaboration with GETH
in collaboration with GETH
Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and Argentina. We provide a global snapshot of the CRC patterns, how screening is performed, and compared/contrasted to the genetic profile of Lynch syndrome (LS) in the region. From the literature, we find that only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC, and also with a low adherence. We describe a genetic profile of LS, including a total of 2,685 suspected families, where confirmed LS ranged from 8% in Uruguay and Argentina to 60% in Peru. Among confirmed LS, path_MLH1 variants were most commonly identified in Peru (82%), Mexico (80%), Chile (60%), and path_MSH2/EPCAM variants were most frequently identified in Colombia (80%) and Argentina (47%). Path_MSH6 and path_PMS2 variants were less common, but they showed important presence in Brazil (15%) and Chile (10%), respectively. Important differences exist at identifying LS families in Latin American countries, where the spectrum of path_MLH1 and path_MSH2 variants are those most frequently identified. Our findings have an impact on the evaluation of the patients and their relatives at risk for LS, derived from the gene affected. Although the awareness of hereditary cancer and genetic testing has improved in the last decade, it is remains deficient, with 39%–80% of the families not being identified for LS among those who actually met both the clinical criteria for LS and showed MMR deficiency.

1 September 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
AVAdriana Della Valle
Adriana Della Valle
BRBenedito Mauro Rossi
Benedito Mauro Rossi
EPEdenir Palmero
Edenir Palmero
MAMarina Antelo
Marina Antelo
CVCarlos Alberto Vaccaro
Carlos Alberto Vaccaro
MDMev Dominguez-Valentin
Mev Dominguez-Valentin

28 June 2017 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
JBJosé Luis Buleje
José Luis Buleje
MGMaría L. Guevara-Fujita
María L. Guevara-Fujita
OAOscar Acosta
Oscar Acosta
FHFrancia D. P. Huaman
Francia D. P. Huaman
PDPierina Danos
Pierina Danos
RFRicardo FUJITA
Ricardo FUJITA
Background Breast cancer is one of the most prevalent malignancies in the world. In Peru, breast cancer is the second cause of death among women. Five to ten percent of patients present a high genetic predisposition due to BRCA1 and BRCA2 germline mutations. Methods We performed a comprehensive analysis of BRCA1 and BRCA2 genes by Sanger sequencing and multiplex ligation‐dependent probe amplification (MLPA) to detect large rearrangements in patients from 18 families, which met the criteria for hereditary breast cancer. Results In this series, we found four pathogenic mutations, three previously reported (BRCA1: c.302‐1G>C and c.815_824dup10; BRCA2: c.5946delT) and a duplication of adenines in exon 15 in BRCA1 gene (c.4647_4648dupAA, ClinVar SCV000256598.1). We also found two exonic and four intronic variants of unknown significance and 28 polymorphic variants. Conclusion This is the first report to determine the spectrum of mutations in the BRCA1/BRCA2 genes in Peruvian families selected by clinical and genetic criteria. The alteration rate in BRCA1/BRCA2 with proven pathogenic mutation was 22.2% (4 out 18) and this finding could be influenced by the reduced sample size or clinical criteria. In addition, we found three known BRCA1/BRCA2 mutations and a BRCA1 c.4647_4648dupAA as a novel pathogenic mutation.

26 December 2024 in Bioinformatics Advances
Verified
Journal Article
Open access
ENEduardo Navarrete-Bencomo
Eduardo Navarrete-Bencomo
Anthony Vladimir Campos SeguraAnthony Vladimir Campos Segura
Anthony Vladimir Campos Segura
OSOrlando Sevillano
Orlando Sevillano
AMAna Mayanga
Ana Mayanga
JBJosé Luis Buleje
José Luis Buleje
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
Motivation: The Cancer Cell Line Encyclopedia (CCLE), launched in 2008, systematically organizes multi-omic and pharmacological data from over 1000 cancer cell lines with molecular dependency maps accessible through the DepMap tool. However, DepMap lacks tools for systematic comparison of mRNAs, miRNAs, proteins, and metabolites, as well as their links to drug responses and gene signatures. Extracting this data externally requires bioinformatics expertise, limiting access for wet-lab researchers. Results: We developed ShinyTHOR, a web app for intuitive access to multi-omic (transcriptomic, metabolomic, methylomic, proteomic, and miRNomic) and drug-related data. It integrates datasets from CCLE, miRTarBase, circInteractome, and the Genomics of Drug Sensitivity in Cancer. ShinyTHOR includes six modules: (1) identifying top/bottom ten cell lines by marker expression or drug IC50, (2) single-sample Gene Set Enrichment Analysis (ssGSEA), (3) multi-analyte expression evaluation, (4) miRNA-target interactions across cancer types, (5) miRNA impact on mRNA translation via protein levels, and (6) circRNA/miRNA modulation. To validate its utility, we applied ShinyTHOR to a gastric cancer prognosis study (GES7). Availability and implementation: ShinyTHOR is freely accessible for non-commercial use at https://alexismurillo.shinyapps.io/ShinyThor, with source code available at https://github.com/Murillo22/ShinyThor.

1 February 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
OAOscar Acosta
Oscar Acosta
JPJaime Ponce
Jaime Ponce
JCJosé Cotrina
José Cotrina
AAAlfredo Aguilar
Alfredo Aguilar
JBJosé Luis Buleje
José Luis Buleje
Background: Cell‐free DNA (cfDNA) is used in clinical research to identify biomarkers for diagnosis of and follow‐up on cancer. Here, we propose a fast and innovative approach using traditional housekeeping genes as cfDNA targets in a copy number analysis. We focus on the application of highly sensitive technology such as digital PCR (dPCR) to differentiate breast cancer (BC) patients and controls by quantifying regions of PUM1 and RPPH1 (RNase P) in plasma samples.Methods: We conducted a case‐control study with 82 BC patients and 82 healthy women. cfDNA was isolated from plasma using magnetic beads and quantified by spectrophotometry to estimate total cfDNA. Then, both PUM1 and RPPH1 genes were specifically quantified by dPCR. Data analysis was calibrated using a reference genomic DNA in different concentrations.Results: We found RNase P and PUM1 values were correlated in the patient group (intraclass correlation coefficient [ICC] = 0.842), but they did not have any correlation in healthy women (ICC = 0.519). In dPCR quantification, PUM1 showed the capacity to distinguish early‐stage patients and controls with good specificity (98.67%) and sensitivity (100%). Conversely, RNase P had lower cfDNA levels in triple‐negative BC patients than luminal subtypes (p < 0.025 for both), confirming their utility for patient classification.Conclusion: We propose the PUM1 gene as a cfDNA marker for early diagnosis of BC and RNase P as a cfDNA marker related to hormonal status and subtype classification in BC. Further studies with larger sample sizes are warranted.

7 August 2023 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDPierina Danos
Pierina Danos
SGStefano Giannoni‐Luza
Stefano Giannoni‐Luza
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
OAOscar Acosta
Oscar Acosta
MGMaria Luisa Guevara‐Fujita
Maria Luisa Guevara‐Fujita
JBJosé Luis Buleje
José Luis Buleje
Background: Promoter hypermethylation is one of the enabling mechanisms of hallmarks of cancer. Tumor suppressor genes like RARB and GSTP1 have been reported as hypermethylated in breast cancer tumors compared with normal tissues in several populations. This case–control study aimed to determine the association between the promoter methylation ratio (PMR) of RARB and GSTP1 genes (separately and as a group) with breast cancer and its clinical‐pathological variables in Peruvian patients, using a liquid biopsy approach.Methods: A total of 58 breast cancer patients and 58 healthy controls, matched by age, participated in the study. We exacted cell‐free DNA (cfDNA) from blood plasma and converted it by bisulfite salts. Methylight PCR was performed to obtain the PMR value of the studied genes. We determined the association between PMR and breast cancer, in addition to other clinicopathological variables. The sensitivity and specificity of the PMR of these genes were obtained.Results: A significant association was not found between breast cancer and the RARB PMR (OR = 1.90; 95% CI [0.62–6.18]; p = 0.210) or the GSTP1 PMR (OR = 6.57; 95% CI [0.75–307.66]; p = 0.114). The combination of the RARB + GSTP1 PMR was associated with breast cancer (OR = 2.81; 95% CI [1.02–8.22]; p = 0.026), controls under 50 years old (p = 0.048), patients older than 50 (p = 0.007), and postmenopausal (p = 0.034). The PMR of both genes showed a specificity of 86.21% and a sensitivity of 31.03%.Conclusion: Promoter hypermethylation of RARB + GSTP1 genes is associated with breast cancer, older age, and postmenopausal Peruvian patients. The methylated promoter of the RARB + GSTP1 genes needs further validation to be used as a biomarker for liquid biopsy and as a recommendation criterion for additional tests in asymptomatic women younger than 50 years.